Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase 3 trial of deferiprone in pantothenate kinase-associated neurodegeneration (PKAN)
2012-000845-11Phase 3Completed
- Sponsor
- ApoPharma Inc.
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pantothenate kinase-associated neurodegeneration (PKAN) comparing Deferiprone with Placebo (2 arms). Primary endpoint: Change in dystonia severity (BAD scale). Started Mar 2012; status: completed.
02
Drugs
deferiprone
03
Conditions
pantothenate kinase-associated neurodegeneration (PKAN)
Beyond the preview
Go deeper on 2012-000845-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000845-11.